Join us for National Brain Tumor Society’s 2015 Scientific Summit
District Hall, 75 Northern Avenue, Boston, MA October 15, 2015, 8:30 AM – 5:00 PM
National Brain Tumor Society’s new 2015 Scientific Summit is an incredible day that brings together renowned leaders from all aspects of the brain tumor field — many actively engaged in our ground-breaking research initiatives — to share our collaborative work, explore emerging opportunities, and build strong and diverse partnerships to fast-track new discoveries toward a cure.
This year we will focus exclusively on where scientific progress is being made through our shared work:
8:30 – 8:50 AM Welcome and Overview
- Carrie Treadwell, National Brain Tumor Society, Chief Research Officer
- David Arons, National Brain Tumor Society, Interim Chief Executive Officer
8:50 – 12:00 PM Defeat GBM Research Collaborative Scientific Review Session
Leadership of each research core will report out on their progress and latest findings, bringing synergistic discussion and review to stimulate faster progress. In addition we will discuss two new areas of interest, Immunotherapy and a game-changing, Global Adaptive Trial.
Facilitator: Dr. WK Al Yung, MD Anderson Cancer Center, Defeat GBM Scientific Director
- Core 1: Discovery — Frank Furnari, PhD, Ludwig Institute, UCSD, Defeat GBM PI
- Core 2: Drug Development — John de Groot, MD, MD Anderson Cancer Center, Defeat GBM PI
- Core 2: Drug Development — Ingo Mellinghoff, MD, Memorial Sloan Kettering Cancer Center, Defeat GBM PI
- Core 3: Biomarker — Paul Mischel, MD, Ludwig Institute UCSD, Defeat GBM PI and Tim Cloughesy, MD, University of California, LA, Defeat GBM PI
12:25 – 12:55 PM Defeat Pediatric High Grade Glioma Research Collaborative (Lunch Presentation)
Data sharing, collaboration, and translational discoveries must be better supported in all brain tumor research, especially for pediatric patients. Learn more about the Defeat Pediatric High Grade Glioma Research Collaborative and how the CURE Platform will address those needs.
- Carrie Treadwell, Pediatric Cancer Cure, LLC, President
- Nada Jabado, MD, PhD, Montreal Children’s Hospital, Defeat pHGG PI
- Sabine Mueller, MD, PhD, UCSF, Pacific Neuro-Oncology Consortium, Defeat pHGG PI
1:00 PM – 3:00 PM Community Research Fund: Oligodendroglioma
Our funded researchers will discuss their findings to date and opportunities in the next area of investment will be explored.
Facilitator: Dr. WK Al Yung, MD Anderson Cancer Center, NBTS Strategic Advisor
- IDH1R132H-induced transformation of oligodendrocyte progenitor cells into oligodendroglioma — Anders Persson, PhD, University of California, San Francisco
- Mapping the epigenomic landscape of oligodendroglioma to elucidate tumor growth and chemosensitivity — Mario Suva, MD, PhD, MA General Hospital, Harvard Medical School
- The functional biology of germline predisposition to oligodendroglioma — Robert Jenkins, MD, PhD, Mayo Clinic
- Research Overview: Identifying Opportunities — Ann Kingston, PhD, National Brain Tumor Society, Associate Director of Scientific Operations
- New Community Collaboratives – LOGLIO: Susan Chang, MD, University of California, San Francisco
3:10 – 4:50 PM Community Research Fund: Metabolic Therapy
The state of the field in relation to nutrition and wellness, specifically looking at metabolic therapy and the opportunities for exploration and investment, will be discussed in order to formalize a plan for this work.
Facilitator: Robert Strausberg, PhD, Ludwig Institute for Cancer Research, Exec. Director of Collaborative Sciences
- Patient Perspective — Chandri Navarro, National Brain Tumor Society, Board of Directors and Que Collins, PhD, KetoTherapeutics Food Company, Cancer Immunologist, Cancer Widower
- Research Overview: Identifying Opportunities — Jennifer Helfer, PhD, National Brain Tumor Society, Associate Director of Scientific Operations
- Ketogenic diet for the treatment of brain tumors: a pluripotent therapy whose time has come — Adrienne Scheck, PhD, Barrow Neurological Institute
- Defining dose and strategy for diet therapy in gliomas — Jaishri Blakeley, MD, Johns Hopkins School of Medicine
- Dissecting the interaction between oncogenes and the environment to identify targetable metabolic vulnerabilities in glioblastoma — Paul Mischel, MD, Ludwig Institute for Cancer Research, San Diego
4:50 – 5:00 PM Closing and Thank You
- Michael Nathanson, National Brain Tumor Society, Board of Directors, Chairman
The RSVP deadline has passed and this event is now at capacity. If would like to put your name on a waiting list or have any questions, please reach out to Amanda Bates at email@example.com or 516.632.8880.
For more information about attending our Grey Gala on October 14th, please visit braintumor.org/bostongala.